Patient (Pt) Reported Pain In Men With Metastatic Castration-Resistant Prostate Cancer (Mcrpc) Receiving Talazoparib (Tala): Talapro-1

F. Saad,J. S. De Bono,P. Barthelemy,T. Dorff,N. Mehra,G. Scagliotti,A. Stirling,J-P. Machiels,V. Renard,M. Maruzzo,C. S. Higano,H. P. Gurney,C. Healy,H. Bhattacharyya,B. Arondekar,A. Niyazov,K. Fizazi

ANNALS OF ONCOLOGY（2021）

引用 0|浏览9

暂无评分

摘要

In TALAPRO-1, TALA showed promising antitumor activity and manageable toxicity. A secondary objective was change from baseline in pt reported pain, measured by the Brief Pain Inventory-Short Form (BPI-SF).

查看译文

关键词

talazoparib,prostate cancer,castration-resistant

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要